Tumor Regressions Observed During Combination Treatment with a Bi-Steric mTORC1-Selective Inhibitor and a KRAS G12C-Selective Inhibitor in Preclinical Lung Cancer Model that is Resistant to KRAS G12 C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results